Bullous pemphigoid treated with dexamethasone-cyclophosphamide pulse therapy
DOI:
https://doi.org/10.66344/jpad.v28i2.1071Keywords:
Bullous pemphigoid, dexamethasone-cyclophosphamide pulse therapy, DCPAbstract
Objective To induce permanent remission in bullous pemphigoid patients.
Methods 5 patients of bullous pemphigoid treated with dexamethasone-cyclophosphamide pulse (DCP) therapy are being reported. Diagnosis was confirmed by histopathology and immunofluorescence test. Each pulse comprised of dexamethasone 100 mg dissolved in 500 ml of glucose and transfused intravenously over 1-1.5 hours on three consecutive days. On 2nd day cyclophosphamide 500 mg was transfused through the same drip. It was repeated every 28 days. In between oral cyclophosphamide 50mg daily was given. The whole treatment was divided into 4 phases: phase I, till all the lesions cleared; phase II, no lesions but still DCP was given for 9 months; phase III DCP withdrawn, only oral cyclophosphamide 50mg daily was given for 9 months; and in phase IV, all the treatment was withdrawn and patients are followed-up as much as possible. Period of remission was noted.
Results Out of five, three patients entered into remission up to 7.5 years after stoppage of all treatment. Remaining two are in remission for one to two years.
Conclusion Dexamethasone-cyclophosphamide pulse therapy is able to induce permanent remission in bullous pemphigoid.
References
1. Pasricha JS, Gupta R. Pulse therapy with dexamethasone in Reiter’s disease (A case report). Indian J Dermatol Venereol Leprol. 1982;48:358-61.
2. Pasricha JS, Gupta R. Pulse therapy with dexamethasone cyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol. 1984;50:199-203.
3. Gupta R. Prolonged remission of pemphigus induced by dexamethasone cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol. 2007;73:121-3.
4. Gupta R, Gupta S, Gupta A. Efficiency and safety of dexamethasone cyclophosphamide pulse therapy in the treatment of pemphigus – An open randomized controlled study. Apollo Medicine. 2015;12:243-7.
5. Gupta R, Gupta S, Khera V. Systemic lupus erythematosus response to dexamethasone –cyclophosphamide pulse therapy. J Dermatolog Treatment 2008; 20:55-8
6. Pasricha JS, Ramam M, Shah S. Reversal of systemic sclerosis with dexamethasone pulse therapy. Indian J Dermatol Venereol Leprol. 1990;56:40-2.
7. Gupta R. Systemic sclerosis treated with dexamethasone pulse therapy. Indian J Dermatol Venereol Leprol. 2003;69:191-2.
8. Pasricha JS, Reddy R, Nandakishore T Khera V. Pyoderma gangrenosum treated with dexamethasone pulse therapy. Indian J Dermatol Venereol Leprol. 1991;57:225-8.
9. Gupta R, Gupta S. Dexamethasone cyclophosphamide pulse therapy in lichen amyloidosis : A case report. J Dermatolog Treat. 2007;18:249-51.
10. Gutpa R, Gupta S. Peyronie’s disease treated with oral weekly dexamethasone and continuous low dose cyclophosphamide. Indian J Dermatol Venereol Leprol. 2014;59:317.
11. Gupta R. Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol. 2016;82:239-41.
12. Gupta R. Prolonged remission of rheumatoid arthritis with dexamethasone-cyclophosphamide pulse therapy: A case series. Indian J Rheumatol. 2014;2:98-100.
13. Khandpur S, Verma P. Bullous pemphigoid. Indian J Dermatol Venereol Leprol. 2011;77:450-5.
14. Appelhans M, Bonsman S, Orge C, Bröcker EB. Dexamethasone-cyclophosphamide pulse therapy in bullous auto-immune dermatology. Hautarzt. 1993;44:143-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Ramji Gupta
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
